11 December 2019
ImmuPharma PLC
("ImmuPharma" or the "Company")
SHARE PRICE VOLATILITY
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, we note the volatility in the Company's share price and speculation concerning a possible fundraising. The Board can confirm that the Company is adequately funded and has no intention of raising funds.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
ImmuPharma PLC (www.immupharma.com) Tim McCarthy, Chairman |
+ 44 (0) 207 152 4080 |
Dimitri Dimitriou, Chief Executive Officer |
|
Lisa Baderoon, Head of Investor Relations |
+ 44 (0) 7721 413496 |
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Vassil Kirtchev Stanford Capital Partners (Joint Broker) Patrick Claridge, John Howes SI Capital (Joint Broker) Nick Emerson |
+44 (0) 203 368 8974 +44 (0) 203 815 8880 +44 (0) 1483 413500 |
|
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. For additional information about ImmuPharma please visit www.immupharma.com.
